Purchase and Sale of Shares and PDMR Shareholdings

RNS Number : 5524H

Diaceutics PLC

07 April 2022

 

7 April 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Purchase and Sale of Shares and PDMR Shareholdings

Diaceutics PLC , ( AIM: DXRX), the diagnostic commercialisation company announces the following Director and PDMR share dealings.

On 5 April 2022, Nick Roberts, CFO of Diaceutics, purchased 39,179 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of £1.015 pence per Ordinary Share. As a result of the purchase, Nick's shareholding is 39,179 Ordinary Shares, representing approximately 0.05 % of the Company's issued share capital.

On 6 April 2022, Deborah Davis, the Chair of Diaceutics, purchased 20,000 Ordinary Shares at an average price of £1.0125 pence per share. As a result of the purchase, Deborah's shareholding is 64,800 Ordinary Shares, representing approximately 0.08 % of the Company's issued share capital.

On 6 April 2022, Charles Hindson, Non-Executive Director of Diaceutics, purchased 20,000 Ordinary Shares at a price of £1.01 pence per share. As a result of the purchase, Charles' shareholding is 63,500 Ordinary Shares, representing approximately 0.08 % of the Company's issued share capital.

Across 5 and 6 April 2022, Philip White, a PDMR, sold 200,000 Ordinary Shares at an average price of £0.989 pence per Ordinary Share. As a result of Philip's sale, the beneficial holding of Philip White and his connected parties in the Company is 1,406,389 Ordinary Shares, representing 1.67 % of the Company's issued share capital.

Enquiries:

Diaceutics PLC
Nick Roberts, Chief Financial Officer	Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: [phone]
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR	Tel: [phone]
Caroline Forde	[e-mail]
Kieran Breheny
Matthew Young

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Nick Roberts
2	Reason for notification
a.	Position/Status	CFO
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £ 0.002 each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)		Share purchase:
			Price(s)	Volume(s)
			£1.015	39,179
d.	Date of the transaction	5 April 2022
e.	Place of the transaction	AIM Market of the London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Deborah Davis
2	Reason for notification
a.	Position/Status	Chair
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £ 0.002 each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)		Share purchase:
			Price(s)	Volume(s)
			£1.01 £1.02	15,000 5,000
d.	Date of the transaction	6 April 2022
e.	Place of the transaction	AIM Market of the London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Charles Hindson
2	Reason for notification
a.	Position/Status	Non-Executive Director
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £ 0.002 each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)		Share purchase:
			Price(s)	Volume(s)
			£1.01	20,000
d.	Date of the transaction	6 April 2022
e.	Place of the transaction	AIM Market of the London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Philip White
2	Reason for notification
a.	Position/Status	PDMR
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Sale
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			£1.01 £0.98	60,000 140,000
e.	Date of the transaction	5 & 6 April 2022
f.	Place of the transaction	AIM Market of the London Stock Exchange

 

END

 

 

DSHFLFIASFIRIIF